 |
|
New study finds advanced liver cancer patients live longer by taking anti-cancer drug sorafenib
July 24, 2008Researchers at Mount Sinai School of Medicine in New York have found that sorafenib (Nexavar) helps patients with advanced liver cancer live about 44 percent longer compared with patients who did not receive the anti-cancer drug. The findings, published in the July 23rd, 2008 issue of the New England Journal of Medicine, is a significant advance in the management of liver cancer, which is the third cause of cancer death globally, often resulting in death within a year of diagnosis.
"This is the first time that we've had an effective systemic treatment for liver cancer," said Josep Llovet, MD, Director of Research in Liver Cancer at Mount Sinai School of Medicine in New York, and a Professor at the Barcelona Clinic Liver Cancer (BCLC) Group in Barcelona, Spain and lead author of the study. "Our findings demonstrated survival advantages that are both statistically significant and clinically meaningful."
Sorafenib, a tablet that is taken orally, is approved in the United States for treating a form of advanced kidney cancer, and is currently being evaluated in patients with other cancers. Some 40 percent of liver cancers (and up to 80 percent in Asia and sub-Saharan Africa) are diagnosed at an advanced stage. Therapy for advanced liver cancer may include surgery (if possible), radiation therapy and/or regional chemotherapy (delivered directly into the liver). However, no systemic treatment-anti-cancer medication that enters the bloodstream, either as an oral or intravenous medicine-has proven effective to date for advanced liver cancer.
Dr. Llovet and his associates examined overall survival and the time it took for cancer to grow among patients with previously untreated liver cancer who were randomly assigned to receive either 400 mg of sorafenib twice daily (299 patients) or a placebo (303 patients).
Patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to the positive findings, the study was terminated early.
The incidence of adverse side effects was similar between the two groups (52 percent in the sorafenib group and 54 percent for placebo). The most common moderate to serious side effects were diarrhea (11 percent vs. 2 percent), skin reactions in the hands and feet (8 percent vs. 1 percent), fatigue (10 percent vs. 15 percent) and bleeding (6 percent vs. 9 percent).
The Mount Sinai Hospital / Mount Sinai School of Medicine
Dr. Llovet and his associates examined overall survival and the time it took for cancer to grow among patients with previously untreated liver cancer who were randomly assigned to receive either 400 mg of sorafenib twice daily (299 patients) or a placebo (303 patients).
Patients who received sorafenib lived a median of 10.7 months compared with 7.9 months for those who received a placebo. Time to cancer progression was also significantly longer in the treatment group: 5.5 vs. 2.8 months. Due to the positive findings, the study was terminated early.
The incidence of adverse side effects was similar between the two groups (52 percent in the sorafenib group and 54 percent for placebo). The most common moderate to serious side effects were diarrhea (11 percent vs. 2 percent), skin reactions in the hands and feet (8 percent vs. 1 percent), fatigue (10 percent vs. 15 percent) and bleeding (6 percent vs. 9 percent).
The Mount Sinai Hospital / Mount Sinai School of Medicine
Liver Cancer Current Events and Liver Cancer News RSSHepatitis B exposure may increase risk for pancreatic cancer
In a first-of-its-kind finding, researchers at The University of Texas M. D. Anderson Cancer Center have discovered that exposure to the hepatitis B virus (HBV) may increase the risk of pancreatic cancer.
Gene variant boosts risk of fatty liver disease, scientists discover
Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.
To protect against liver disease, body puts cells 'under arrest'
A stable form of cell-cycle arrest known to offer potent protection against cancer also limits liver fibrosis, a condition characterized by an excess of fibrous tissue, according to a new report in the August 22nd Cell, a Cell Press publication.
Senescence in liver cells is found by CSHL scientists to help limit acute tissue damage
Although post-reproductive life in humans is often associated with decline and a loss of powers, an analogous state in certain cells -- called senescence -- is proving to be one of ironic potency. Scientists at Cold Spring Harbor Laboratory (CSHL) today reported that a particular class of senescent liver cells orchestrates a sequence of events in living mice that can limit fibrosis, a natural response of the liver to acute damage.
Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes
Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD).
Hepatitis C virus may need enzyme's help to cause liver disease
A key enzyme may explain how hepatitis C infection causes fatty liver - a buildup of excess fat in the liver, which can lead to life-threatening diseases such as cirrhosis and liver cancer, report University of Pittsburgh Graduate School of Public Health and School of Medicine researchers.
New therapy shows promise for fighting treatment-resistant cancer cells
A gene radiotherapy system that detects and treats cancer cells that are resistant to traditional forms of chemotherapy and radiation showed success in the laboratory and could eventually prove beneficial for cancer patients, according to researchers at SNM's 55th Annual Meeting.
CSHL scientists trace causal link between a tumor suppressor gene and liver cancer
Scientists at Cold Spring Harbor Laboratory (CSHL) have taken the search for cancer-causing genes an important step forward. In a newly published paper, they confirm that a gene called DLC1 is a tumor suppressor. They have demonstrated in living mice that its deletion, inactivation or loss precipitates events culminating in an aggressive type of liver cancer closely related to common human epithelial cancers of the liver (also known as hepatocellular carcinoma, or HCC).
Study concludes no racial disparities in long-term outcomes in recipients of liver transplants
New research published in the Journal of the American College of Surgeons shows long-term survival and liver rejection rates are equivalent for African-American liver transplant patients as compared with patients of other races.
Researchers Find New Treatment for Hepatitis C
Researchers at the OU Health Sciences Center have found a new use for an old drug. Their findings appear online Friday in the American Journal of Gastroenterology.
More Liver Cancer Current Events and Liver Cancer News Articles
 | 100 Q&A About Liver Cancer (100 Questions & Answers about . . .) by Ghassan K. Abou-Alfa Written by two prominent physicians at Memorial Sloan - Kettering Cancer Center and filled with insider advice from actual patients, this book is an invaluable resource for anyone coping with the physical and emotional turmoil of this frightening... |
 | The Official Patient's Sourcebook on Adult Primary Liver Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to adult primary liver cancer (also Cancer liver; Cholangiocarcinoma;... |
| Liver Cancer Risk from Internally-Deposited Radionuclides: Recommendations of the National Council on Radiation Protection and Measurements (Ncrp Report, No. 135) by National Council on Radiation Protection and Measurements | |
 | Liver Cancer (M.D. Anderson Solid Tumor Oncology Series) Liver Cancer, the inaugural volume in the M.D. Anderson Solid Tumor Oncology series, provides the general surgeon, surgical oncologist, and medical oncologist with the most up-to-date and current standard of multimodality care for hepatobiliary cancer. Surgical approaches, chemotherapy, immunotherapy, gene therapy, and radiotherapy are all presented, giving the practitioner a much needed,... |
 | Viruses and Liver Cancer (Perspectives in Medical Virology) by E. Tabor Hepatocellular carcinoma (HCC) is one of the most important complications of chronic viral hepatitis. It usually results in a fatal outcome if not discovered in its earliest stages. Its close association with the hepatitis B and C viruses makes it one of the first human cancers for which there is strong evidence of a viral cause. For this reason it provides a model for studying viral... |
| Liver Cancer (International Agency for Research on Cancer) by Iarc | |
| Gale Encyclopedia of Cancer: Liver biopsy by Ph.D. Lata Cherath The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs,... | |
| Liver Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science) by Tamra Orr | |
 | Geographic and Demographic Distribution of Liver Cancer Mortality in Bexar County Texas for the Period 1990 - 1998 This is a AIR FORCE INST OF TECH WRIGHT-PATTERSONAFB OH report procured by the Pentagon and made available for public release. It has been reproduced in the best form available to the Pentagon. It is not spiral-bound, but rather assembled with Velobinding in a soft, white linen cover. The Storming Media report number is A140183. The abstract provided by the Pentagon follows: The objective of this... |
 | Liver Cell Cancer (Digestive Diseases) |
| © 2008 BrightSurf.com |